A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with
advanced solid tumors and varying degrees of hepatic impairment.